Compile Data Set for Download or QSAR
maximum 50k data
Found 142 Enz. Inhib. hit(s) with all data for entry = 2545
TargetGlutamate receptor ionotropic, NMDA 1/2B(Homo sapiens (Human))
Cadent Therapeutics

US Patent
LigandPNGBDBM370772(US10239835, Example 00324)
Affinity DataIC50:  4.41nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 1/2B(Homo sapiens (Human))
Cadent Therapeutics

US Patent
LigandPNGBDBM370754(US10239835, Example 00306)
Affinity DataIC50:  4.44nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 1/2B(Homo sapiens (Human))
Cadent Therapeutics

US Patent
LigandPNGBDBM370814(US10239835, Example 00365)
Affinity DataIC50:  5.24nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 1/2B(Homo sapiens (Human))
Cadent Therapeutics

US Patent
LigandPNGBDBM370813(US10239835, Example 00364)
Affinity DataIC50:  5.25nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 1/2B(Homo sapiens (Human))
Cadent Therapeutics

US Patent
LigandPNGBDBM370756(US10239835, Example 00308)
Affinity DataIC50:  5.72nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 1/2B(Homo sapiens (Human))
Cadent Therapeutics

US Patent
LigandPNGBDBM370745(US10239835, Example 00297)
Affinity DataIC50:  5.96nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 1/2B(Homo sapiens (Human))
Cadent Therapeutics

US Patent
LigandPNGBDBM370743(US10239835, Example 00295)
Affinity DataIC50:  6.20nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 1/2B(Homo sapiens (Human))
Cadent Therapeutics

US Patent
LigandPNGBDBM370781(US10239835, Example 00333)
Affinity DataIC50:  6.81nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 1/2B(Homo sapiens (Human))
Cadent Therapeutics

US Patent
LigandPNGBDBM370815(US10239835, Example 00366)
Affinity DataIC50:  8.30nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 1/2B(Homo sapiens (Human))
Cadent Therapeutics

US Patent
LigandPNGBDBM370816(US10239835, Example 00367)
Affinity DataIC50:  8.5nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 1/2B(Homo sapiens (Human))
Cadent Therapeutics

US Patent
LigandPNGBDBM370769(US10239835, Example 00321)
Affinity DataIC50:  8.62nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 1/2B(Homo sapiens (Human))
Cadent Therapeutics

US Patent
LigandPNGBDBM370797(US10239835, Example 00349)
Affinity DataIC50:  8.78nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 1/2B(Homo sapiens (Human))
Cadent Therapeutics

US Patent
LigandPNGBDBM370802(US10239835, Example 00354)
Affinity DataIC50:  9.36nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 1/2B(Homo sapiens (Human))
Cadent Therapeutics

US Patent
LigandPNGBDBM370768(US10239835, Example 00320)
Affinity DataIC50:  9.60nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 1/2B(Homo sapiens (Human))
Cadent Therapeutics

US Patent
LigandPNGBDBM370744(US10239835, Example 00296)
Affinity DataIC50:  10.7nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 1/2B(Homo sapiens (Human))
Cadent Therapeutics

US Patent
LigandPNGBDBM370676(US10239835, Example 00228)
Affinity DataIC50:  13nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 1/2B(Homo sapiens (Human))
Cadent Therapeutics

US Patent
LigandPNGBDBM370678(US10239835, Example 00230)
Affinity DataIC50:  14nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 1/2B(Homo sapiens (Human))
Cadent Therapeutics

US Patent
LigandPNGBDBM370782(US10239835, Example 00334)
Affinity DataIC50:  14.4nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 1/2B(Homo sapiens (Human))
Cadent Therapeutics

US Patent
LigandPNGBDBM370755(US10239835, Example 00307)
Affinity DataIC50:  16.8nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 1/2B(Homo sapiens (Human))
Cadent Therapeutics

US Patent
LigandPNGBDBM370727(US10239835, Example 00279)
Affinity DataIC50:  17.8nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 1/2B(Homo sapiens (Human))
Cadent Therapeutics

US Patent
LigandPNGBDBM370681(US10239835, Example 00233)
Affinity DataIC50:  17.8nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 1/2B(Homo sapiens (Human))
Cadent Therapeutics

US Patent
LigandPNGBDBM370694(US10239835, Example 00246)
Affinity DataIC50:  18nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 1/2B(Homo sapiens (Human))
Cadent Therapeutics

US Patent
LigandPNGBDBM370809(US10239835, Example 00361)
Affinity DataIC50:  19.2nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 1/2B(Homo sapiens (Human))
Cadent Therapeutics

US Patent
LigandPNGBDBM370817(US10239835, Example 00368)
Affinity DataIC50:  20nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 1/2B(Homo sapiens (Human))
Cadent Therapeutics

US Patent
LigandPNGBDBM370812(US10239835, Example 00363)
Affinity DataIC50:  20.6nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 1/2B(Homo sapiens (Human))
Cadent Therapeutics

US Patent
LigandPNGBDBM370749(US10239835, Example 00301)
Affinity DataIC50:  20.9nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 1/2B(Homo sapiens (Human))
Cadent Therapeutics

US Patent
LigandPNGBDBM370757(US10239835, Example 00309)
Affinity DataIC50:  21.7nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 1/2B(Homo sapiens (Human))
Cadent Therapeutics

US Patent
LigandPNGBDBM370784(US10239835, Example 00336)
Affinity DataIC50:  23.4nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 1/2B(Homo sapiens (Human))
Cadent Therapeutics

US Patent
LigandPNGBDBM370794(US10239835, Example 00346)
Affinity DataIC50:  26.3nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 1/2B(Homo sapiens (Human))
Cadent Therapeutics

US Patent
LigandPNGBDBM370801(US10239835, Example 00353)
Affinity DataIC50:  26.7nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 1/2B(Homo sapiens (Human))
Cadent Therapeutics

US Patent
LigandPNGBDBM370767(US10239835, Example 00319)
Affinity DataIC50:  29.3nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 1/2B(Homo sapiens (Human))
Cadent Therapeutics

US Patent
LigandPNGBDBM370714(US10239835, Example 00266)
Affinity DataIC50:  30.2nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 1/2B(Homo sapiens (Human))
Cadent Therapeutics

US Patent
LigandPNGBDBM370722(US10239835, Example 00274)
Affinity DataIC50:  30.5nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 1/2B(Homo sapiens (Human))
Cadent Therapeutics

US Patent
LigandPNGBDBM370740(US10239835, Example 00292)
Affinity DataIC50:  37.6nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 1/2B(Homo sapiens (Human))
Cadent Therapeutics

US Patent
LigandPNGBDBM370800(US10239835, Example 00352)
Affinity DataIC50:  38nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 1/2B(Homo sapiens (Human))
Cadent Therapeutics

US Patent
LigandPNGBDBM370765(US10239835, Example 00317)
Affinity DataIC50:  41.1nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 1/2B(Homo sapiens (Human))
Cadent Therapeutics

US Patent
LigandPNGBDBM370711(US10239835, Example 00263)
Affinity DataIC50:  41.5nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 1/2B(Homo sapiens (Human))
Cadent Therapeutics

US Patent
LigandPNGBDBM370698(US10239835, Example 00250)
Affinity DataIC50:  46.4nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 1/2B(Homo sapiens (Human))
Cadent Therapeutics

US Patent
LigandPNGBDBM370675(US10239835, Example 00227)
Affinity DataIC50:  47nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 1/2B(Homo sapiens (Human))
Cadent Therapeutics

US Patent
LigandPNGBDBM370702(US10239835, Example 00254)
Affinity DataIC50:  47.4nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 1/2B(Homo sapiens (Human))
Cadent Therapeutics

US Patent
LigandPNGBDBM370787(US10239835, Example 00339)
Affinity DataIC50:  50.8nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 1/2B(Homo sapiens (Human))
Cadent Therapeutics

US Patent
LigandPNGBDBM370712(US10239835, Example 00264)
Affinity DataIC50:  51.6nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 1/2B(Homo sapiens (Human))
Cadent Therapeutics

US Patent
LigandPNGBDBM370705(US10239835, Example 00257)
Affinity DataIC50:  52.1nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 1/2B(Homo sapiens (Human))
Cadent Therapeutics

US Patent
LigandPNGBDBM370721(US10239835, Example 00273)
Affinity DataIC50:  53.2nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 1/2B(Homo sapiens (Human))
Cadent Therapeutics

US Patent
LigandPNGBDBM370689(US10239835, Example 00241)
Affinity DataIC50:  53.4nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 1/2B(Homo sapiens (Human))
Cadent Therapeutics

US Patent
LigandPNGBDBM370758(US10239835, Example 00310)
Affinity DataIC50:  55.2nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 1/2B(Homo sapiens (Human))
Cadent Therapeutics

US Patent
LigandPNGBDBM370718(US10239835, Example 00270)
Affinity DataIC50:  57.3nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 1/2B(Homo sapiens (Human))
Cadent Therapeutics

US Patent
LigandPNGBDBM370683(US10239835, Example 00235)
Affinity DataIC50:  58.3nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 1/2B(Homo sapiens (Human))
Cadent Therapeutics

US Patent
LigandPNGBDBM370799(US10239835, Example 00351)
Affinity DataIC50:  60.2nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 1/2B(Homo sapiens (Human))
Cadent Therapeutics

US Patent
LigandPNGBDBM370677(US10239835, Example 00229)
Affinity DataIC50:  61.6nMAssay Description:Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Displayed 1 to 50 (of 142 total ) | Next | Last >>
Jump to: